FDA Accepts GSK's sNDA for Zejula as a First-Line Maintenance Treatment in Ovarian Cancer

GlaxoSmithKline’s Zejula could soon be used as a first-line maintenance treatment for certain types of ovarian cancer. On Monday, the U.S. Food and Drug Administration accepted the company’s submission of a supplemental New Drug Application for the new indication.